ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Drug Development for Neglected Tropical Diseases: DNDi and the Product Development Partnership (PDP) Model
Abstract
Abstract
Neglected tropical diseases (NTDs), including leishmaniasis, Chagas disease, sleeping
sickness, dengue fever, and schistosomiasis to name a few, are endemic in 149 countries
and impact 1.4 billion people- often the most vulnerable groups in the poorest countries
(WHO 2016). Unfortunately, many of these diseases have no vaccines to prevent them,
nonexistent or incredibly problematic treatments, and limited resources dedicated
to monitoring, controlling, and improving the situation of those who are infected.
These diseases may impact millions of people, but the affected population is too poor
to exert economic sway and attract investment under the current medical research and
development system, and a long-standing market failure has left their needs unmet.
However, since the turn of the century, the growing humanitarian concern for NTDs
has prompted exploration into innovative partnership and financing mechanisms for
developing health technologies for these diseases. Product development partnerships
(PDPs), such as the Drugs for Neglected Disease Initiative (DNDi), have emerged to
coordinate new collaborations between private industry, academia, and the public sector.
Furthermore, the political landscape around NTDs is changing as exemplified by the
fact that the World Health Organization (WHO) is endorsing demonstration projects
to experiment with "delinkage" principles that aim to separate the innovation market
from the price of products and increase affordability and access. These novel approaches
to drug development are important case studies in understanding how to best address
the market failure around diseases of poverty and offer insight as to what strategies
effectively advance the development of innovative health technologies. The lessons
learned from the activities of DNDi and other PDPs shed light on how to align the
goals of global health with political and economic realities.
Type
Honors thesisSubject
PDPproduct development partnership
public-private partnership
access to medicines
neglected tropical disease
Permalink
https://hdl.handle.net/10161/11869Citation
Tuttle, Julia (2016). Drug Development for Neglected Tropical Diseases: DNDi and the Product Development
Partnership (PDP) Model. Honors thesis, Duke University. Retrieved from https://hdl.handle.net/10161/11869.Collections
More Info
Show full item record
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.
Rights for Collection: Undergraduate Honors Theses and Student papers
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info